First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results Meeting Abstract
| Authors: | Rudin, C. M.; Kim, H. R.; Navarro, A.; Gottfried, M.; Peters, S.; Csőszi, T.; Cheema, P. K.; Rodriguez-Abreu, D.; Wollner, M.; Czyżewicz, G.; Yang, J. C. H.; Mazieres, J.; Orlandi, F. J.; Luft, A.; Gümüş, M.; Kato, T.; Kalemkerian, G. P.; Fu, W.; Zhao, B.; El-Osta, H. |
| Abstract Title: | First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results |
| Meeting Title: | 2022 World Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 17 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2022 Aug 6-9 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S33 |
| End Page: | S34 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.07.063 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: OA12.06 -- Located within section named "OA12 Novel And Combination Strategies For SCLC" -- Source: Cinahl |
